Innate Pharma S.A. (IPHA)
NASDAQ: IPHA
· Real-Time Price · USD
1.84
-0.03 (-1.60%)
At close: Jun 17, 2025, 3:59 PM
1.87
1.63%
After-hours: Jun 17, 2025, 04:00 PM EDT
-1.60% (1D)
| Bid | 1.79 |
| Market Cap | 169.57M |
| Revenue (ttm) | 12.62M |
| Net Income (ttm) | -49.47M |
| EPS (ttm) | -0.7 |
| PE Ratio (ttm) | -2.63 |
| Forward PE | 7.23 |
| Analyst | Buy |
| Ask | 2.18 |
| Volume | 6,439 |
| Avg. Volume (20D) | 24,428 |
| Open | 1.86 |
| Previous Close | 1.87 |
| Day's Range | 1.83 - 1.86 |
| 52-Week Range | 1.29 - 3.51 |
| Beta | 0.98 |
About IPHA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IPHA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IPHA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+20.62%
Innate Pharma shares are trading higher after the ...
Unlock content with
Pro Subscription
6 months ago
+29.25%
Innate Pharma shares are trading higher after the company announced its TELLOMAK Phase 2 trial of Lacutamab demonstrated significant symptom relief and quality of life improvements.
4 weeks ago · businesswire.com
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual MeetingMARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drugs i...
